Geron and University of Edinburgh collaborate on development of cell types derived from human embryonic stell cells
Geron Corporation and the University of Edinburgh have entered into a collaboration to conduct preclinical safety and efficacy studies with three cell types derived from human embryonic stem cells (hESCs). The cell types are hepatocytes for the treatment of liver failure and osteoblasts and chondrocytes for the treatment of musculoskeletal disorders, including osteoarthritis, bone fractures and osteoporosis. The studies, based at the University's Centre for regenerative medicine, will be under the direction of Professor John Iredale, Dr. Phil Newsome, Dr. Brendon Noble and Professor Hamish Simpson.
"The milestones and endpoints of these programs were collaboratively defined, with Geron contributing its expertise on the design and execution of IND-enabling (Investigational New Drug) studies," said Dr. Jane Lebkowski, Geron's senior vice president of regenerative medicine. "We are enthusiastic about conducting these studies at the University of Edinburgh because of the infrastructure in place at the New Royal Infirmary in Little France. Moreover, the lead investigators include experienced hESC researchers and practicing physicians whose expertise will be useful to progress these cell types to the clinic."
Other news from the department science

New Label-Free Imaging Tracks Cancer Treatment in Single Cells
One Tool, Many Applications

The evolution of cancer cells decoded
"Our vision is a new type of early cancer detection"

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Clinical_Research_Coordinator
Acipimox only to be used as additional or alternative treatment - CMDh endorses PRAC recommendation

"Biohackers" TV series stored on DNA - Synthetic genetic material as a stable storage medium - for over 1000 years
